SEC Comment Letter 0000000000-23-005359 to ARROWHEAD PHARMACEUTICALS, INC. (ARWR) (CIK 0000879407) (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) (CIK 0000879407)
Date: May 19, 2023 · CIK: 0000879407 · Accession: 0000000000-23-005359
AI Filing Summary & Sentiment
File numbers found in text: 001-38042
Letter
United States securities and exchange commission logo May 19, 2023 Kenneth Myszkowski Chief Financial Officer Arrowhead Pharmaceuticals, Inc. 177 E. Colorado Blvd, Suite 700 Pasadena, California 91105 Re:Arrowhead Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended September 30, 2022 Filed November 28, 2022 File No. 001-38042 Dear Kenneth Myszkowski: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 19, 2023
Kenneth Myszkowski
Chief Financial Officer
Arrowhead Pharmaceuticals, Inc.
177 E. Colorado Blvd, Suite 700
Pasadena, California 91105
Re:Arrowhead Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended September 30, 2022
Filed November 28, 2022
File No. 001-38042
Dear Kenneth Myszkowski:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences